secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001157523-24-000014
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra advances RASP modulator pipeline; multiple IND submissions and trial initiations planned for 2024
--------------------------------------------------------------------------------

- Positive biomarker results from ADX-629 in Sjögren-Larsson Syndrome adult cohort; pediatric expansion submission expected H1 2024.
- Phase 2 trial of ADX-629 in moderate alcoholic hepatitis initiated; top-line results expected H2 2024.
- IND for ADX-246 submitted for phase 1 in healthy volunteers; expected to expand to atopic dermatitis patients; top-line results H2 2024.
- IND for ADX-248 expected in 2024 for phase 1/2 in dry AMD with dark adaptation deficit.
- De-prioritized ADX-629 in chronic cough and idiopathic nephrotic syndrome; new preclinical RASP modulator program in metabolic disease initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752324000014/0001157523-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752324000014/a53876982.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer